Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARiPSCTcells

Financiado

Cerrado

Generation of safe and efficient off the shelf chimeric antigen receptor CAR...

Generation of safe and efficient off the shelf chimeric antigen receptor CAR engineered T cells for broad application The feasibility and effectiveness of adoptive T cell therapies for cancer has now been proven in several clinical settings. Yet, the current approaches are still individual-tailored and thus, their progress and broader use is limi... ver más

30/06/2017

STICHTING AMSTERDA...

166K€

Presupuesto del proyecto: 166K€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-06-30

MSCA-IF-2014-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

STICHTING AMSTERDAM UMC

123.28K€ | Lider

STICHTING VU

42.32K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CARLY Development and characterization of a novel CAR T-cell thera... 226K€ Cerrado

CARAT Chimeric Antigen Receptors CARs for Advanced Therapies 6M€ Cerrado

EURE-CART EURopean Endeavour for Chimeric Antigen Receptor Therapies 6M€ Cerrado

SynCAR-Ts Synthetic Chimeric Antigen Receptors: Hijacking Nitrenium Io... 3M€ Cerrado

TALE Therapeutic Allele Engineering A novel technology for cell... 2M€ Cerrado

PolyAntiTumor Polyclonal anti-tumor immunity by engineered human T cells 2M€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2015-04-28
Fecha Fin: 2017-06-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 166K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The feasibility and effectiveness of adoptive T cell therapies for cancer has now been proven in several clinical settings. Yet, the current approaches are still individual-tailored and thus, their progress and broader use is limited. Having rapid access to off-the-shelf, safe cellular products, which can be applied across histocompatibility limitations, would greatly benefit the broader applicability of adoptive T cell therapy. To this end, the applicant recently reported, in a proof-of-concept study, that genetic engineering of T-cell derived induced pluripotent stem cells (TiPSC) with Chimeric Antigen Receptors (CARs) can be an efficient strategy to concomitantly harness the unlimited availability of induced pluripotent stem cells and direct the specificity and functional potential of TiPSC-derived T cells in an HLA-independent manner. Based on this technology, this proposal aims to further investigate novel stem cell genetic engineering strategies in order to obtain in vitro, unlimited, safe and broadly applicable T cells targeting Multiple Myeloma (MM). We propose to target MM with a novel CD38-targeting CAR (CD38CAR). Since CD38 is not a MM-specific target, we aim to simultaneously tackle the on-target/off-tumor toxicity by introducing a drug-regulated expression of CD38CAR. In addition, we aim to use the CRISPR/Cas9 system to achieve targeted knockout of the endogenous T cell receptor (TCR) and the HLA antigens on the CAR-engineered TiPSCs (CARTiPSC) in order to extend the applicability of CARTiPSC-derived T cells across HLA-barriers. The success of this proposal will lay the foundation for further translational application of CARTiPSC-derived T cells cells and investigation of new strategies to enhance their effector function and persistence.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores